301 related articles for article (PubMed ID: 10785598)
1. Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed.
Peters GJ; van Triest B; Backus HH; Kuiper CM; van der Wilt CL; Pinedo HM
Eur J Cancer; 2000 May; 36(7):916-24. PubMed ID: 10785598
[TBL] [Abstract][Full Text] [Related]
2. Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates.
Backus HH; Pinedo HM; Wouters D; Kuiper CM; Jansen G; van Groeningen CJ; Peters GJ
Oncol Res; 2000; 12(5):231-9. PubMed ID: 11417748
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines.
Backus HH; Wouters D; Ferreira CG; van Houten VM; Brakenhoff RH; Pinedo HM; Peters GJ
Eur J Cancer; 2003 Jun; 39(9):1310-7. PubMed ID: 12763222
[TBL] [Abstract][Full Text] [Related]
4. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
5. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
Van Triest B; Pinedo HM; Giaccone G; Peters GJ
Ann Oncol; 2000 Apr; 11(4):385-91. PubMed ID: 10847455
[TBL] [Abstract][Full Text] [Related]
6. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels.
Giovannetti E; Backus HH; Wouters D; Ferreira CG; van Houten VM; Brakenhoff RH; Poupon MF; Azzarello A; Pinedo HM; Peters GJ
Br J Cancer; 2007 Mar; 96(5):769-75. PubMed ID: 17339891
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 induction.
Neuteboom ST; Karjian PL; Boyer CR; Beryt M; Pegram M; Wahl GM; Shepard HM
Mol Cancer Ther; 2002 Apr; 1(6):377-84. PubMed ID: 12477050
[TBL] [Abstract][Full Text] [Related]
8. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
9. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.
van der Wilt CL; Kuiper CM; Peters GJ
Oncol Res; 1999; 11(8):383-91. PubMed ID: 10803742
[TBL] [Abstract][Full Text] [Related]
10. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates.
Longley DB; Boyer J; Allen WL; Latif T; Ferguson PR; Maxwell PJ; McDermott U; Lynch M; Harkin DP; Johnston PG
Cancer Res; 2002 May; 62(9):2644-9. PubMed ID: 11980662
[TBL] [Abstract][Full Text] [Related]
11. Schedule-dependent interaction between raltitrexed and 5-fluorouracil in human colon cancer cell lines in vitro.
Kano Y; Akutsu M; Suzuki K; Yazawa Y; Tsunoda S; Furukawa Y
Oncol Res; 2000; 12(3):137-48. PubMed ID: 11216672
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
Mirjolet JF; Barberi-Heyob M; Didelot C; Peyrat JP; Abecassis J; Millon R; Merlin JL
Br J Cancer; 2000 Nov; 83(10):1380-6. PubMed ID: 11044365
[TBL] [Abstract][Full Text] [Related]
13. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status.
Violette S; Poulain L; Dussaulx E; Pepin D; Faussat AM; Chambaz J; Lacorte JM; Staedel C; Lesuffleur T
Int J Cancer; 2002 Apr; 98(4):498-504. PubMed ID: 11920608
[TBL] [Abstract][Full Text] [Related]
14. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells.
Matsui SI; Arredondo MA; Wrzosek C; Rustum YM
Cancer Res; 1996 Oct; 56(20):4715-23. PubMed ID: 8840989
[TBL] [Abstract][Full Text] [Related]
15. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
Backus HH; Pinedo HM; Wouters D; PadrĂ³n JM; Molders N; van Der Wilt CL; van Groeningen CJ; Jansen G; Peters GJ
Int J Cancer; 2000 Sep; 87(6):771-8. PubMed ID: 10956384
[TBL] [Abstract][Full Text] [Related]
16. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins.
Nita ME; Nagawa H; Tominaga O; Tsuno N; Fujii S; Sasaki S; Fu CG; Takenoue T; Tsuruo T; Muto T
Br J Cancer; 1998 Oct; 78(8):986-92. PubMed ID: 9792140
[TBL] [Abstract][Full Text] [Related]
17. p53 and WAF1 are induced and Rb protein is hypophosphorylated during cell growth inhibition by the thymidylate synthase inhibitor ZD1694 (Tomudex).
Yin MB; Voigt W; Panadero A; Vanhoefer U; Frank C; Pajovic S; Azizkhan J; Rustum YM
Mol Pharmacol; 1997 Apr; 51(4):630-6. PubMed ID: 9106628
[TBL] [Abstract][Full Text] [Related]
18. Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells.
van der Wilt CL; Smid K; Aherne GW; Noordhuis P; Peters GJ
Eur J Cancer; 1997 Mar; 33(3):471-8. PubMed ID: 9155534
[TBL] [Abstract][Full Text] [Related]
19. A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.
Jackman AL; Melin CJ; Kimbell R; Brunton L; Aherne GW; Theti DS; Walton M
Biochim Biophys Acta; 2002 Jul; 1587(2-3):215-23. PubMed ID: 12084463
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks.
Wang W; McLeod HL; Cassidy J; Collie-Duguid ES
Cancer Chemother Pharmacol; 2007 May; 59(6):839-45. PubMed ID: 17119966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]